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Symposium: Elderly: Health economics  
 
 
SP-0243   
Cost-effectiveness data to guide treatment decisions for 
elderly patients: focus on radiotherapy 
A. Louie1 
1London Health Sciences Centre, Department of Radiation 
Oncology, London, Canada  
  
As a disease of the elderly, cancer poses a unique public 
health problem worldwide. Elderly patients with cancer are 
less likely to receive guideline-based treatment and/or 
participate in clinical trials. At the individual patient level, 
competing risk, perceived efficacy of treatment, and various 
levels of patient/physician preferences all contribute to 
heterogeneity in treatment decision-making. At the 
population level, the economic impact of this variability is 
significant. Costs incurred in the prevention, diagnosis, 
treatment and surveillance of cancer are rising at a rate 
disproportionate to what healthcare systems are able to 
afford. Cost-effectiveness research can be employed to 
determine the suitability of radiotherapy in elderly cancer 
populations through modeling or in the context of clinical 
trials.  Using stereotactic radiotherapy in early stage lung 
cancer as an example, the principals of cost-effectiveness 
research will be explored. Concepts such as cost calculations, 
quality adjusted life expectancy, utilities, and incremental 
cost effectiveness ratios will be introduced. 
   
SP-0244   
From co-morbidity and toxicity to quality of life: A black 
hole in economic evaluations of radiotherapy? 
E. Moser1 
1Fundação Champalimaud, Department of Radiotherapy, 
Lisboa, Portugal  
  
Cancer is increasingly becoming a disease affecting the lives 
of the elderly, especially in more developed countries. Over 
the last 30 years, many patients have experienced the 
mortality lowering benefits of earlier diagnosis and more 
effective treatments. At the same time, the elderly 
population is demographically fast increasing, pronouncing 
even higher prevalence and incidence rates in the near 
future. Among other co-morbidities, second or third cancers 
are not an exception any more. 
Because of large individual variations in physical and mental 
conditions and personal preference of the patient and/or 
family, the treatment decisions seem difficult to fit into 
guidelines. Inclusion in clinical trials is rare. 
Overall, elderly receive (adjuvant) radiotherapy 
and chemotherapy less often, probably because of fear 
for higher rate of complications. In clinical surveys, however, 
elderly don´t suffer from more complications than younger 
patients, except for cardiac complications and postoperative 
death. For most tumours relative survival is lower for the 
elderly, except for patients with colon cancer, prostate 
cancer or indolent NHL. Co-morbidity seems to have an 
independent prognostic effect, except for tumours with a 
very poor prognosis. 
Alternative research strategies need to be sought to improve 
insights on causes of death in this population. Special 
attention is needed for the economical impact of over- versus 
under treatment. Both palliative care and complications 
generate high costs, but reports on costs are rare. Often 
quality of life surveys are lacking late outcome and decision-
making trade offs. Registry based surveys can help insights in 
population-based decision-making, but are lacking co-
morbidity and toxicity data. 
Guidelines are needed to reduce over-treatment but also 
under-treatment, taking into account life-expectancy and co-
morbidities in all our cancer patients. 
   
SP-0245   
Is it time to design specific radiotherapy trials for the 
elderly, and how can we integrate the economic 
perspective? 
J. Van Loon1 
1MAASTRO Clinic, Radiation Oncology, Maastricht, The 
Netherlands  
 
More than 60% of cancer patients is older than 65 years, a 
figure that only will increase the coming decades. As elderly 
patients are underrepresented in clinical trials, treatment 
recommendations for the general population cannot 
straightforwardly be extrapolated to the elderly. 
It is anticipated that intensified treatment regimens are less 
effective in elderly due to physiologic changes occurring with 
aging. Furthermore, higher toxicity rates are expected given 
the high rates of comorbidities and generally poorer 
performance status. Hence, the balance between the 
benefits and risks of a treatment will be different for this 
patient group. In fact, this balance will be different for each 
individual elderly patient: although it is reasonable to spare 
the patient with severe comorbidities or a bad performance 
status an intensive treatment from which he is unlikely to 
benefit and that might even decrease quality of life (QoL), 
the one that is medically fit may benefit from such an 
intensive treatment. Furthermore, given the limited life 
expectancy, QoL and preservation of independence and 
cognition are important to take into account.  
For these reasons, there is an urgent need to design clinical 
trials specific for the elderly, build evidence to guide 
treatment selection in this group and implement it in clinical 
practice. First, reliable tools are needed to distinguish the 
subgroup of fit patients from frail patients, i.e. those 
expected to experience important toxicity. Until now, this 
decision is rather subjective as it is based primarily on the 
physician’s perception whether a patient is deemed fit 
enough to undergo a certain treatment. Geriatric 
assessments have shown to be more predictive for survival, 
dependency and toxicities than age or performance status in 
elderly treated with chemotherapy (Freyer, Ann Oncol 2005; 
Hurria, JCO 2011; Maione JCO 2005), but these have not been 
validated for radiotherapy. The fact that a full geriatric 
assessment is time consuming and is not always reimbursed 
makes it difficult to implement in routine clinical practice. 
Therefore, the EORTC recommends a minimum dataset data 
(MinDS) to be collected, which takes max 5 minutes to 
complete (Pallis, Ann Oncol 2011). It is anticipated that this 
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dataset will evolve over time as more data become available. 
Secondly, “classical” trial end points such as overall and 
progression free survival may not be the most appropriate 
outcome measures in elderly-specific trials. Given the limited 
life expectancy, QoL is essential to take into account, and 
also, cost-effectiveness will be different from the general 
population. This makes quality adjusted survival, measured in 
quality adjusted life years (QALYs), a more suitable end 
point, allowing the answer to both questions: it reflects both 
the quantity of lifetime gained and the value of this time, 
and it provides a direct outcome measure to calculate the 
cost-effectiveness of the treatment. In order to calculate 
QALYs, utility scores should be collected prospectively. The 
EuroQoL 5 Dimensions (EQ-5D), a short questionnaire 
consisting of five questions, is most frequently used for this 
purpose.  
General and disease specific quality of life, toxicity and 
preservation of functional capacity are interesting secondary 
end points, scored with a uniform and internationally 
acknowledged scoring system. The additional use of the 
elderly specific questionnaire EORTC QLQ-ELD15 is 
recommended, which has recently been validated 
internationally (Wheelwright, Br J Cancer 2013).   
Results from surveys indicate that the large majority of 
elderly patients would be willing to participate in trials 
(Comis, JCO 2003; Townsley BMC Cancer 2006), but care 
should be taken to limit the complexity of the trial design 
and burden of study related examinations. 
   
 
Proffered Papers: Physics 5: New technology and its 
clinical implementation  
 
 
OC-0246   
Clinical implementation of online MR-guided adaptive 
radiotherapy for abdominopelvic malignancies 
J. Olsen1, P. Parikh1, D. Yang1, T. Zhao1, H. Wooten1, H. Li1, 
V. Rodriguez1, L. Olsen1, C. Robinson1, J. Michalski1, S. 
Mutic1, R. Kashani1 
1Washington University Medical Center, Radiation Oncology, 
St. Louis, USA  
 
Purpose/Objective: Online adaptive MR-IGRT was recently 
implemented at our institution. We report workflow 
considerations and initial clinical experience with online 
adaptive MR-IGRT for abdominopelvic malignancies. 
Materials and Methods: The first clinically deployed online 
adaptive MR-IGRT system consists of a split 0.35T MR scanner 
straddling a ring gantry with three MLC-equipped 60Co heads. 
The unit is supported by a fast Monte Carlo based treatment 
planning system allowing real-time adaptive planning with 
the patient on the table. All patients undergo CT- and MR-
simulation for initial treatment planning. A high-resolution 
volumetric MR image is acquired for each patient at the time 
of daily treatment setup. Deformable registration is 
performed using the original simulation CT dataset from 
initial treatment planning, which allows the transfer of the 
initial contours and the electron density map to the 
localization MR of the day. The deformed electron density 
map is then used to recalculate the original plan on the 
anatomy of the day for physician evaluation. Physician re-
contouring and plan re-optimization are performed when 
required, and patient-specific quality assurance is performed 
using an independent Monte Carlo calculation for online 
adaptive QA. The tool also allows for verification of plan 
parameters against the original plan. 
Results: Online adaptive MR-IGRT was implemented in 
September of 2014. Five patients with abdominopelvic 
malignancies have been treated with planned evaluation for 
treatment adaptation in the first 2 months. The clinical 
setting included neoadjuvant rectosigmoid (n=3), 
unresectable gastric, and unresectable pheochromocytoma. 
MR localization images were used to recalculate dose online 
for all cases. Re-contouring and re-optimization was deemed 
necessary for 3/5, while the initial plan deemed sufficient for 
2/5 cases. Reasons for plan adaptation included change in 
target size, weight loss, and change in small bowel anatomy. 
The approximate times required for online dose calculation, 
re-contouring, re-optimization, and QA were 2, 15, 2, and 5 
minutes, respectively. Treatment utilizing the online 
adaptive plan was completed successfully for all cases when 
deemed necessary. 
Conclusions: Online adaptive MR-IGRT has been successfully 
implemented with planning and QA workflow suitable for 
routine clinical application. Clinical trials are in development 
to formally evaluate adaptive treatment of bladder, 
pancreatic, and oligometastatic abdominal malignancies. 
 
   
OC-0247   
Determination of the optimal tolerance for MLC positioning 
in sliding window and VMAT techniques 
V. Hernandez1, R. Abella1, J.F. Calvo2, D. Jurado-Bruggeman3, 
I. Sancho4, P. Carrasco5 
1Hospital Sant Joan de Reus, Medical Physics, Reus, Spain  
2Hospital Quirón, Medical Physics, Barcelona, Spain  
3Institut Català d'Oncologia, Medical Physics, Girona, Spain  
4Institut Català d'Oncologia, Medical Physics, L'Hospitalet de 
Llobregat, Spain  
5Hospital de la Santa Creu i Sant Pau, Medical Physics, 
Barcelona, Spain  
 
Purpose/Objective: Several authors have recommended a 2 
mm tolerance for MLC positioning in sliding window 
treatments. A tolerance of 5mm is typically used in VMAT 
treatments, but the optimal value for this technique remains 
unknown. In this paper we present the results of a 
multicentric study to determine the optimal tolerance for 
both techniques. 
Materials and Methods: The procedure used to investigate 
the optimal tolerance is based on dynalog file analysis. The 
study was performed with seven Varian linear accelerators 
(linacs) (Varian Medical Systems, Inc., Palo Alto, CA) from 
five different centers. All linacs were equipped with dynamic 
MLCs: six with the Millennium120 model and one with the 
high definition HD120 model. Dynalogs were collected from 
over 100,000 clinical treatments and an in-house software 
was developed for dynalog analysis. By using this software 
the number of tolerance faults was computed as a function of 
the user-defined tolerance and the optimal value for this 
tolerance tolerance –defined as the lowest achievable value- 
